Differential Properties of Janus Kinase Inhibitors in the Treatment of Immune-mediated Inflammatory Diseases
Rheumatology (Oxford) 2023 doi 10.1093/rheumatology/kead448 Epub ahead of print
JAKis differ in structure, which affects their inhibitory concentration for different JAKs.
This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.
Baricitinib and tofacitinib are not associated with notable haematological changes versus other JAKis. Furthermore, differences in JAKi metabolism and elimination result in differing recommendations and dose modifications in patients with renal and hepatic impairments.
Keywords:
